文献速递糖尿病肥胖与代谢综合征

普通人群血浆钙卫蛋白与新发2型糖尿病:一项前瞻性队列研究

Plasma Calprotectin and New-onset Type 2 Diabetes in the General Population: A Prospective Cohort Study.
PubMed 文献 · J Clin Endocrinol Metab · 2024-01-01

在PREVEND前瞻性人群队列4815名基线非糖尿病参与者中,基线血浆钙卫蛋白中位数为0.49 mg/L,其水平与新发2型糖尿病风险显著相关(每倍增HR 1.42)。该关联在进一步校正混杂因素后不再显著,高脂血症和高敏C反应蛋白可解释此变化。

要点

  • 血浆钙卫蛋白每倍增与新发2型糖尿病风险相关,年龄性别校正后HR 1.34。
  • 进一步校正混杂因素后关联不再显著(HR 1.11,95%CI 0.90-1.37,P=0.326)。
  • 高血压、心血管病史、HOMA-IR和降脂药使用存在显著效应修饰。

核心结论

  • 普通人群中血浆钙卫蛋白升高与新发2型糖尿病风险较高相关,可能是一种可改变的炎症生物标志物。
  • 该关联并不代表直接效应,似乎依赖于高脂血症和全身性炎症。

研究设计与样本

  • 前瞻性人群队列研究(PREVEND),纳入4815名基线非糖尿病参与者,检测基线血浆钙卫蛋白水平。
  • 新发2型糖尿病定义为空腹血糖≥7.0 mmol/L、随机血糖≥11.1 mmol/L、自报医生诊断的2型糖尿病、使用降糖药或上述任意组合。

主要发现

  • 血浆钙卫蛋白中位数为0.49(0.35-0.69)mg/L。
  • 血浆钙卫蛋白与新发2型糖尿病风险显著相关(每倍增HR 1.42,95%CI 1.22-1.66,P<0.001)。
  • 校正年龄和性别后关联仍独立(HR 1.34,95%CI 1.14-1.57,P<0.001),但进一步校正潜在混杂因素后不再显著(HR 1.11,95%CI 0.90-1.37,P=0.326),其中高脂血症和高敏C反应蛋白的校正解释了显著性的丧失。
  • 分层分析显示高血压、心血管疾病史、HOMA-IR(交互作用P≤0.001)和降脂药使用(交互作用P≤0.05)存在显著效应修饰,无高血压、无心血管疾病史、HOMA-IR低于中位数和未使用降脂药者HR较高。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Systemic inflammation plays a pivotal role in the development of type 2 diabetes (T2D). OBJECTIVE: We hypothesized that circulating levels of calprotectin, a myeloid cell-derived biomarker of inflammation, is associated with the development of new-onset T2D in the general population. METHODS: A total of 4815 initially nondiabetic participants of the Prevention of Renal and Vascular End-stage Disease (PREVEND), a prospective population-based cohort study, were assessed for plasma levels of calprotectin at baseline. Circulating levels of calprotectin were investigated for potential associations with the risk of new-onset T2D, defined as a fasting plasma glucose level of 7.0 mmol/L or greater, a random plasma glucose level of 11.1 mmol/L or greater, a self-reported physician-based diagnosis of T2D, the use of glucose-lowering drugs, or any combinations thereof. RESULTS: Median plasma calprotectin levels were 0.49 (0.35-0.69) mg/L. Plasma calprotectin levels were significantly associated with the risk of new-onset T2D (hazard ratio [HR] per doubling 1.42 [95% CI, 1.22-1.66]; P < .001). The association remained independent of adjustment for age and sex (HR 1.34 [95% CI, 1.14-1.57]; P < .001), but not after further adjustment for potentially confounding factors (HR 1.11 [95% CI, 0.90-1.37]; P = .326), with adjustment for hyperlipidemia and high-sensitivity C-reactive protein explaining the loss of significance. Stratified analyses showed significant effect modification by hypertension, history of cardiovascular disease (CVD), the Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) (Pinteraction ≤ .001 for each), and the use of lipid-lowering drugs (Pinteraction ≤ .05), with higher HRs in individuals without hypertension, without history of CVD, with below-median HOMA-IR, and in those not using lipid-lowering drugs. CONCLUSION: Elevated plasma levels of calprotectin are associated with a higher risk of developing T2D in the general population and may represent a moveable inflammatory biomarker. This association, however, does not represent a direct effect, and seems dependent on hyperlipidemia and systemic inflammation.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Bourgonje AR, Bourgonje MF, Sokooti S, et al. Plasma Calprotectin and New-onset Type 2 Diabetes in the General Population: A Prospective Cohort Study. J Clin Endocrinol Metab. 2024. PMID: 38436468. doi:10.1210/clinem/dgae130

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。